Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125425021 | 12542502 | 1 | I | 20160624 | 20160709 | 20160709 | EXP | GB-CIPLA LTD.-2016GB08952 | CIPLA | CRABB SJ, BRADBURY J, NOLAN L, SELMAN D, MUTHURAMALINGAM SR, CAVE J ET AL.,. A PHASE I CLINICAL TRIAL OF IRINOTECAN AND CARBOPLATIN IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER. CHEMOTHERAPY. 2012;58:257 TO 263 | 0.00 | Y | 0.00000 | 20160709 | OT | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125425021 | 12542502 | 1 | PS | Irinotecan | IRINOTECAN | 1 | Intravenous (not otherwise specified) | 50 MG/M2, ON DAYS 1 AND 8 | U | U | 77219 | 50 | MG/M**2 | ||||||
| 125425021 | 12542502 | 2 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | AUC OF 5, ON DAY 1 | U | U | 0 | ||||||||
| 125425021 | 12542502 | 3 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Oral | UNKNOWN | U | U | 0 | ||||||||
| 125425021 | 12542502 | 4 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Oral | UNKNOWN | U | U | 0 | ||||||||
| 125425021 | 12542502 | 5 | SS | Vincristine | VINCRISTINE | 1 | Unknown | UNKNOWN | U | U | 0 | ||||||||
| 125425021 | 12542502 | 6 | SS | Doxorubicin | DOXORUBICIN | 1 | Unknown | UNKNOWN | U | U | 0 | ||||||||
| 125425021 | 12542502 | 7 | C | ATROPINE. | ATROPINE | 1 | Unknown | UNKNOWN | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125425021 | 12542502 | 1 | Small cell lung cancer extensive stage |
| 125425021 | 12542502 | 2 | Small cell lung cancer extensive stage |
| 125425021 | 12542502 | 3 | Small cell lung cancer extensive stage |
| 125425021 | 12542502 | 4 | Small cell lung cancer extensive stage |
| 125425021 | 12542502 | 5 | Small cell lung cancer extensive stage |
| 125425021 | 12542502 | 6 | Small cell lung cancer extensive stage |
| 125425021 | 12542502 | 7 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125425021 | 12542502 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125425021 | 12542502 | Disease progression | |
| 125425021 | 12542502 | Metastasis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |